retatrutide trial phase Severe Obesity Shows 30% Weight Loss Retatrutide Achieves Up to 30.3%

When overall food intake drops, protein intake often drops too, which can increase the risk of muscle loss by breakdown especially if strength training isnt part of your routine

Implications for drugmakers and insurers: GLP-1 medications offer promise for the estimated 4 in 10 US adults with obesity, but short-term use delivers short-lived results

Deliberately increase fluid consumption to compensate

The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: Evidence from human genetic association studies and a mouse model of alcohol dependence

Efficacy of GLP-1 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

The Compounded Semaglutide Ban: What Is Happening in 2026 Here is the short version